Zusammenfassung
Die hepatische Enzephalopathie (HE) ist eine neuropsychiatrische Komplikation akuter und chronischer Lebererkrankungen. Ursache ist eine komplexe, metabolisch induzierte und damit potenziell reversible Funktionsstörung des Gehirns. Voraussetzung für die Diagnose einer HE ist der Nachweis einer Funktionsstörung des zentralen Nervensystems bei gleichzeitig bestehender Leberfunktionsstörung und sicherem Ausschluss einer neurologischen oder psychiatrischen Erkrankung anderer Ätiologie. Die Diagnose einer HE wird rein klinisch gestellt und umfasst ein weites Spektrum neuropsychiatrischer Symptome unterschiedlicher Schweregrade. Die ergänzende Zusatzdiagnostik beinhaltet labormedizinische Methoden, bildgebende Verfahren und neurophysiologische Zusatzuntersuchungen. Die Therapie der HE besteht im Wesentlichen aus der Behandlung und zukünftigen Vermeidung auslösender Faktoren, der Modulation metabolischer Prozesse sowie ultima ratio der Lebertransplantation. Die Prognose hängt von der Art und dem Verlauf der hepatischen Grunderkrankung ab.
Summary
Hepatic encephalopathy (HE) is a neuropsychiatric complication of acute and chronic liver disease. Its etiology and pathogenesis are thought to be a complex, metabolically induced, and therefore potentially reversible disturbance in brain functions. The diagnosis is based on demonstrating both a disorder of the central nervous system and a concomitant liver disease as well as the exclusion of any neurological or psychiatric disorder of other etiology. The diagnosis of HE is clinical and displays a wide spectrum of neuropsychiatric symptoms in different degrees of severity. Ancillary diagnostic workup includes laboratory tests, neuroimaging, and neurophysiological exams such as electroencephalography and evoked potentials. The therapy of HE mainly consists of treatment and avoidance of any precipitating conditions such as high protein intake, infections, and gastrointestinal bleeding. Other therapeutic approaches modulate metabolic processes such as ammonium synthesis and excretion, formation of neurotransmitters, and as a last resort liver transplantation. The prognosis depends ultimately on the course of the liver disease.
Literatur
Amodio P, Del Piccolo F, Marchetti P et al. (1999) Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology 29(6): 1662–1667
Amodio P, Marchetti P, Del Piccolo F et al. (1999) Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin Neurophysiol 110(8): 1334–1344
Baktir G, Fisch HU, Karlaganis G (1987) Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiment with triazolam. Hepatology 7:629–638
Basile AS, Gammal SH, Mullen KD, Jones EA, Skolnick P (1988) Differential responsiveness of cerebellar Purkinje neurons to GABA and benzodiazepin receptor ligands in an animal model of hepatic encephalopathy. J Neurosci 8:2414–2421
Bergeron M, Reader TA, Pomier Layrargues G, Butterworth RF (1989) Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurochem Res 14:853–859
Bernthal P, Hays A, Tarter RE, van Thiel D, Lecky J, Hegedus A (1987) Cerebral CT scan abnormalities in cholestatic and hepatocellular disease and their relationship to neuropsychologic test performance. Hepatology 7:107–114
Bucci L, Palmieri GC (1993) Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr-Med Res Opin 13:109–118
Butterworth RF (1995) Detection of benzodiazepines in hepatic encephalopathy: reply. Hepatology 2:605
Butterworth RF (2000) Complications of cirrhosis III. Hepatic encephalopathy. J Hepatol 32(1): 171–180
Butterworth RF (2000) Hepatic encephalopathy: a neuropsychiatric disorder involving multiple neurotransmitter systems. Curr Opin Neurol 13(6): 721–727
Cordoba J, Blei AT (1997) Treatment of hepatic encephalopathy. Am J Gastroent 92:1429–1439
DeWaele JP, Audet RM, Rose C, Butterworth RF (1997) The portocaval-shunted rat: a new model for the study of the mechanisms controlling voluntary methanol consumption and ethanol dependence. Alcohol Clin Exp Res 21:305–310
Ferenci P (1991) Hepatische Enzephalopathie Klinik der Gegenwart, Urban & Schwarzenberg, München Wien Baltimore
Ferenci P (2001) Hepatic encephalopathy. Dtsch Med Wochenschr 126 [Suppl 1]: 76–80
Ferenci P, Herneth A, Steindl P (1996) Newer approaches to therapy of hepatic encephalopathy. Semin Liver Dis 16:329–338
Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT (2002) Hepatic Encephalopathy—Definition, Nomenclature, Diagnosis, and Quantification: Final Report of the Working Party at the 11th World Congress of Gastroenterology, Vienna 1998. Hepatology 35:716–721
Fischer JE, Baldessarini RJ (1971) False neurotransmitters and hepatic failure. Lancet 2(7715): 75–80
Gabuzda Jr D, Philips GB, Davidson CS (1952) Reversible toxic manifestations in patients with cirrhosis of the liver given cation-exchange resins. N Engl J Med 246:124–130
Gerok W (1984) Hepatische Enzephalopathie. Therapie mit adaptierten Aminosäuren- und Ketosäurengemischen. Therapiewoche 34:49–62
Gerok W, Haeussinger D (1984) Ammonia detoxication and glutamine metabolism in severe liver disease and its role in the pathogenesis of hepatic encephalopathy. In: Haeussinger D, Sies H (eds) Glutamine Metabolism in Mammalian Tissues, Springer, Heidelberg Berlin New York Tokyo, pp. 257–277
Gyr K, Meier R, Haussler J, Bouletreau P, Fleig WE, Gatta A, Holstege A (1996) Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy. Gut 39:319–324
Haeussinger D (1990) Nitrogen metabolism in liver: structural-functional organization and physiological implications. Biochem J 267:281–290
Haeussinger D, Gerok W (1995) Rückwirkungen von Lebererkrankungen auf das Zentralnervensystem: Hepatogene Enzephalopathie. In: Gerok W, Blum HE (eds) Hepatologie, 2nd edn. Urban & Schwarzenberg, München Wien Baltimore pp 845–859
Haeussinger D, Steeb R, Gerok W (1992) Metabolic alkalosis as driving force for urea synthesis in liver disease: pathogenetic model and therapeutic implications. Clin Investig 70(5): 411–415
Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R (1997) Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double blind study. Hepatology 25:1351–1360
Krieger D, Krieger S, Jansen O, Gass P, Theilmann L, Lichtnecker H (1995) Manganese and chronic hepatic encephalopathy. Lancet 346(8970): 270–274
Kullmann F, Hollerbach S, Holstege A, Scholmerich J (1995) Subclinical hepatic encephalopathy: the diagnostic value of evoked potentials. J Hepatol 22(1): 101–110
Lang F, Hauessinger D (1990) Interaction of Cell Volume and Cell Function. Springer, Berlin Heidelberg New York Tokyo
Laubenberger J, Haussinger D, Bayer S, Gufler H, Hennig J, Langer M (1997) Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology 112(5): 1610–1616
Lockwood AH (2002) Positron emission tomography in the study of hepatic encephalopathy. Metab Brain Dis 17(4): 431–435
Lockwood AH, Murphy BW, Donnelly KZ, Mahl TC, Perini S (1993) Positron-emission tomographic localization of abnormalities of brain metabolism in patients with minimal hepatic encephalopathy. Hepatology 18(5): 1061–1068
Lockwood AH, Yap EW, Rhoades HM, Wong WH (1991) Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J Cereb Blood Flow Metab 11(2): 331–336
Lockwood AH, Yap EW, Wong WH (1991) Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 11(2): 337–341
Mendenhall CL, Rouster S, Marshall L, Weesner R (1986) A new therapy for portal systemic encephalopathy. American J Gastroent 81:540–543.
Morgan MY (1996) Noninvasive neuroinvestigation in liver disease. Semin Liver Dis 16(3): 293–314
Naylor CD, O´Rourkee K, Detsky AS, Baker JP (1989) Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A Meta-Analysis. Gastroenterology 97:1033–1042
O'Carroll RE, Hayes PC, Ebmeier KP et al. (1991) Regional cerebral blood flow and cognitive function in patients with chronic liver disease. Lancet 337(8752): 1250–1253
Plauth M, Egberts EH (1993) Was ist gesichert in der Therapie der hepatischen Enzephalopathie? Internist 34:35–42
Pomier Layrargues G (1996) TIPS and hepatic encephaloapthy. Semin Liver Dis 16:315–320
Pomier Layrargues G, Giguére JF, Lavoie J, Perney P, Gagnon S, D'Amour M (1994) Clinical efficacy of benzodiazepine antagonist RO 15–1788 (flumazenil) in cirrhotic patients with hepatic coma: results of a randomized double-blind placebo-controlled crossover trial. Hepatology 19:32–37
Pomier Layrargues G, Spahr L, Butterworth RF (1995) Increased manganese concentrations in pallidum of cirrhotic patients. Lancet 345:735
Pujol A, Pujol J, Graus F et al. (1993) Hyperintense globus pallidus on T1-weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology 43(1): 65–69
Ross B, Kreis R, Farrow NA, Ackermann Z (1992) Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. Radiology 182:19–27
Sanyal AJ, Freedman AM, Shiffman ML, Purdum PP, Luketic VA, Cheatham AK (1994) Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunts: Results of a prospective controlled study. Hepatology 20:46–55
Schomerus H, Schreiegg J (1993) Prevalence of latent portosystemic encephalopathy in an unselected population of patients with liver cirrhosis in general practice. Z Gastroent 31:231–234
Sterns RH, Riggs JE, Schochet SS Jr (1986) Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 314(24): 1535–1542
Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA, de Sa ME (1992) Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 39:542–545
Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS (1992) Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 16:138–144
Tangermann A (1991) The role of mercaptans in the pathogenesis of hepatic encephalopathy. In: Bengtsson F, Jeppsson B, Almdal T, Vilstrup H (eds) Progress in Hepatic Encephalopathy and Metabolic Nitrogen Exchange, CRC Press, Boca Raton, pp 259–270
Tarao K, Ikeda T, Hayashi K, Sakurai A, Okada T, Ito T (1990) Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 31:702–706
Taylor-Robinson SD, Sargentoni J et al. (1994) Cerebral phosphorus-31 magnetic resonance spectroscopy in patients with chronic hepatic encephalopathy. Hepatology 20(5): 1173–1178
Taylor-Robinson SD, Sargentoni J, Marcus CD, Morgan MY, Bryant DJ (1994) Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy. Metab Brain Dis 9(4): 347–359
Taylor-Robinson SD, Sargentoni J et al. (1996) MR imaging and spectroscopy of the basal ganglia in chronic liver disease: correlation of T1-weighted contrast measurements with abnormalities in proton and phosphorus-31 MR spectra. Metab Brain Dis 11(3): 249–268
Timmermann L, Gross J, Dirks M, Volkmann J, Freund HJ, Schnitzler A (2003) The cerebral oscillatory network of parkinsonian resting tremor. Brain 126(Pt 1): 199–212
Weissenborn K, Ehrenheim C, Hori A, Kubicka S, Manns MP (1995) Pallidal lesions in patients with liver cirrhosis: clinical and MRI evaluation. Metab Brain Dis 10(3): 219–231
Zeneroli ML, Cioni G, Vezzelli C, Grandi S, Crisi G, Luzietti R, Ventura E (1987) Prevalence of brain atrophy in liver cirrhosis patients with chronic persistent encephalopathy. Evaluation by computed tomography. J Hepatol 4:283–292
Zieve FJ, Zieve L, Doizaki WM, Gilsdorf RB (1974) Synergism between ammonia and fatty acids in the production of coma: implications for hepatic coma. J Pharmacol Exp Ther 191(1): 10–16
Zieve L, Doizaki WM, Zieve J (1974) Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med 83(1): 16–28
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schellinger, P.D., Hartmann, M.K., Klingmann, C. et al. Hepatische Enzephalopathie. Nervenarzt 74, 1078–1087 (2003). https://doi.org/10.1007/s00115-003-1579-1
Issue Date:
DOI: https://doi.org/10.1007/s00115-003-1579-1